Abstract
Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"
The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.
Author(s):
Warren K. Weston*,Jane A. Harness and Aarthi Narayanan
Abstract | Full-Text | PDF
Share this
30+ Million Readerbase
Abstracted/Indexed in
- Google Scholar
- Open J Gate
- Genamics JournalSeek
- The Global Impact Factor (GIF)
- Open Archive Initiative
- China National Knowledge Infrastructure (CNKI)
- Scimago
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Proquest Summons
- Publons
- MIAR
- ResearchGate
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Secret Search Engine Labs
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences